ZS Acquires Intomics A/S
May 4, 2022
ZS, a global professional services firm, has acquired Copenhagen-based bioinformatics and systems biology company Intomics A/S. The 42-person team and Intomics' curated protein-protein interaction network and analytics capabilities will expand ZS's drug discovery, bioinformatics and R&D offerings to better serve pharmaceutical, biotech and research clients.
- Buyers
- ZS
- Targets
- Intomics A/S
- Industry
- Biotechnology
- Location
- Denmark
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
ZYTOMICS Acquires Applied Spectral Imaging (ASI)
August 6, 2025
Medical Devices
ZYTOMICS, a Berlin-based cancer diagnostics company, has acquired Applied Spectral Imaging (ASI), a leader in digital imaging solutions for pathology and cytogenetics laboratories. The acquisition will integrate ASI's imaging platforms and analysis software with ZYTOMICS' reagents, automation and analytics to create an end-to-end offering for diagnostic labs and accelerate product and technology innovation.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
-
Schrödinger Acquires XTAL BioStructures
January 14, 2022
Biotechnology
Schrödinger, Inc. acquired XTAL BioStructures, Inc., a Natick, Massachusetts–based structural biology services provider, in an all-cash transaction that closed January 14, 2022 for $6 million. The acquisition brings protein production, purification, biophysical methods and X-ray crystallography capabilities in‑house to support Schrödinger's structure-based drug discovery platform and expand its experimental offerings for customers.
-
Kiromic Biopharma Acquires InSilico Solutions
July 26, 2021
Biotechnology
Kiromic Biopharma completed the acquisition of InSilico Solutions via a stock-swap, bringing an in‑house bioinformatics and AI team to support development of its outpatient allogeneic CAR‑T therapies for solid tumors. The deal transfers InSilico’s staff and intellectual assets to Kiromic and is intended to accelerate target/biomarker discovery, manufacturing and clinical development.
-
VeriSIM Life Acquires Molomics Biotech
May 11, 2022
Biotechnology
VeriSIM Life, an AI-driven virtual drug development company based in San Francisco, has acquired Molomics Biotech SL, a Barcelona-based AI-enabled drug discovery firm. The acquisition integrates Molomics' AI + Human Collective Intelligence discovery technology into VeriSIM's BIOiSIM platform to accelerate and improve success rates in drug discovery, including work on Parkinson's disease.
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.